Skip to main content
Signal8

Inventiva S.A. (IVA)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Inventiva S.A. logo

Inventiva S.A.

NASDAQ:IVAHealthcare
-1.58%$3.74
Mkt Cap$894.24M
Float210.85M
O/S239.1M
VOL30K sh
$ Vol$113K
RVOL0.01×
Inst Own36.0%
SI3.9%
Dilution
Inventiva S.A. logoNASDAQ:IVA$3.74-1.58%
Historical Data
DateOpenHighLowCloseVolume
Nov 9, 20263.813.813.713.7329,797
Nov 7, 20263.833.833.833.83100
Nov 6, 20263.633.833.603.802,220,601
Nov 5, 20263.963.963.623.632,535,445
Nov 4, 20264.184.273.853.871,578,939
Nov 3, 20263.804.173.784.034,069,577
Nov 2, 20263.623.993.553.833,248,993
Oct 30, 20263.693.763.583.651,730,070
Oct 29, 20263.753.863.683.731,435,325
Oct 28, 20263.693.773.653.71946,949
Oct 27, 20263.773.853.633.691,782,685
Oct 26, 20263.673.873.643.663,332,166
Oct 23, 20263.533.763.473.714,712,827
Oct 22, 20263.403.633.403.602,399,498
Oct 21, 20263.253.733.253.555,245,725
Oct 20, 20263.003.363.003.262,638,052
Oct 19, 20263.003.092.952.983,953,489
Oct 16, 20263.143.142.902.944,854,758
Oct 15, 20262.983.182.943.112,911,748
Oct 14, 20262.872.962.822.873,150,656
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target (median, last 90d)
$14.00+274.3%
Low $14High $14
Ratings Distribution
BUY
8
HOLD
0
SELL
1
TOTAL9
Insider Trades
No insider transactions for this companyForeign private issuers and non-reporting entities don't file Form 4/5.
Shareholders
36.0%
Institutional
(90)
0.0%
Insiderⓘ
(0)
30.0%
5%+ Owners
(8)
34.1%
Unattributed (incl. retail)ⓘ
Institutional36.0%
5%+ Beneficial30.0%
Unattributed (incl. retail)34.1%
Sources: 13F, 13D/13GO/S: 239.1M · checked 9 Nov 2026 · market-data provider
Insiders & Institutional Holders

Top institutional holders

About

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases.

Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH.

The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease.

In addition, it has a pipeline of earlier stage programs in oncology and other diseases.

The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

Key Metrics
Market Cap$894.24M
Enterprise Value--
P/E Ratio-2.50
Est. Net Cash/Share--
Institutional Ownership35.96%

based on 239.10M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryFRFR
IPO DateJul 10, 2020
Shares Outstanding239.10M
Authorized Shares
Float210.85M
52-Week Range
$2.82$7.29
$3.74(21st percentile)
Volume
Average Daily Volume2.79M
29.80K today vs 2.79M avg(-99%)

30d Avg

2.79M

60d Avg

2.73M

90d Avg

2.10M

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...